Xponance Inc. Has $449,000 Stock Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Xponance Inc. lifted its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 5.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 14,072 shares of the company’s stock after purchasing an additional 749 shares during the quarter. Xponance Inc.’s holdings in Apellis Pharmaceuticals were worth $449,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. JPMorgan Chase & Co. boosted its stake in Apellis Pharmaceuticals by 23.3% during the third quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company’s stock worth $112,036,000 after buying an additional 735,160 shares in the last quarter. Braidwell LP boosted its position in shares of Apellis Pharmaceuticals by 410.8% during the 3rd quarter. Braidwell LP now owns 3,125,183 shares of the company’s stock valued at $90,130,000 after acquiring an additional 2,513,383 shares in the last quarter. Jennison Associates LLC boosted its position in shares of Apellis Pharmaceuticals by 51.6% during the 4th quarter. Jennison Associates LLC now owns 2,760,404 shares of the company’s stock valued at $88,084,000 after acquiring an additional 939,289 shares in the last quarter. Geode Capital Management LLC increased its stake in Apellis Pharmaceuticals by 1.3% in the third quarter. Geode Capital Management LLC now owns 1,810,526 shares of the company’s stock valued at $52,229,000 after acquiring an additional 22,609 shares during the period. Finally, Cibc World Markets Corp acquired a new position in Apellis Pharmaceuticals in the fourth quarter worth about $41,014,000. 96.29% of the stock is currently owned by institutional investors.

Insider Transactions at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, General Counsel David O. Watson sold 5,569 shares of the firm’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $25.10, for a total transaction of $139,781.90. Following the transaction, the general counsel now owns 138,730 shares in the company, valued at approximately $3,482,123. This trade represents a 3.86 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Caroline Baumal sold 2,816 shares of the business’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $33.81, for a total value of $95,208.96. Following the transaction, the insider now owns 55,560 shares of the company’s stock, valued at $1,878,483.60. The trade was a 4.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 66,054 shares of company stock worth $1,952,719 in the last three months. Insiders own 6.80% of the company’s stock.

Analyst Upgrades and Downgrades

APLS has been the topic of several analyst reports. Wedbush lowered their price objective on Apellis Pharmaceuticals from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Monday, March 3rd. HC Wainwright reiterated a “buy” rating and set a $57.00 price objective on shares of Apellis Pharmaceuticals in a research note on Monday, March 3rd. JPMorgan Chase & Co. lifted their price objective on Apellis Pharmaceuticals from $50.00 to $54.00 and gave the company an “overweight” rating in a report on Tuesday, March 4th. The Goldman Sachs Group dropped their target price on shares of Apellis Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating for the company in a research report on Monday, March 3rd. Finally, Royal Bank of Canada reduced their price target on shares of Apellis Pharmaceuticals from $26.00 to $25.00 and set a “sector perform” rating on the stock in a research report on Monday, March 3rd. Eight research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $45.53.

Apellis Pharmaceuticals Stock Performance

Apellis Pharmaceuticals stock opened at $23.79 on Thursday. Apellis Pharmaceuticals, Inc. has a 1 year low of $23.25 and a 1 year high of $59.91. The company’s 50-day moving average is $27.26 and its two-hundred day moving average is $29.74. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. The company has a market cap of $2.99 billion, a PE ratio of -11.72 and a beta of 0.92.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings data on Friday, February 28th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.08. The firm had revenue of $212.50 million for the quarter, compared to analysts’ expectations of $197.92 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The business’s revenue for the quarter was up 45.2% on a year-over-year basis. During the same period last year, the firm earned ($0.73) earnings per share. Equities analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).